CORDIS - Risultati della ricerca dell’UE
CORDIS

European consortium for communicating gene- and cell-based therapy information.

Descrizione del progetto

Informazioni affidabili in merito alle terapie geniche e cellulari

La terapia genica e quella a base cellulare rappresentano una metodologia promettente per varie malattie quali il cancro, la cardiopatia, il diabete e l’AIDS. Il progetto EuroGCT, finanziato dall’UE, svilupperà una gestione affidabile e accessibile delle informazioni sullo sviluppo delle terapie geniche e cellulari per le parti interessate europee. In particolare, fornirà a pazienti, persone affette da patologie, operatori sanitari e cittadini informazioni dettagliate di natura scientifica, legale, etica e sociale, nonché opportunità di coinvolgimento, per supportare l’elaborazione di un processo decisionale più informato in merito alle terapie geniche e cellulari. Inoltre, EuroGCT fornirà alla comunità di ricerca e alle autorità regolatorie e sanitarie informazioni sui passaggi di carattere pratico necessari per lo sviluppo di queste terapie, al fine di contribuire al miglioramento del processo decisionale nei momenti chiave dello sviluppo di nuove terapie in grado di consentire il miglioramento di prodotti.

Obiettivo

The European Consortium for Communicating Gene and Cell Therapy Information (EuroGCT) unites 49 partner organisations and institutions across Europe, including the major European advanced therapies learned societies, with the common goal of providing reliable and accessible information related to cell and gene therapy development to European stakeholders. EuroGCT has two major objectives:
• To provide patients, people affected by conditions, healthcare professionals and citizens with accurate scientific, legal, ethical and societal information and with engagement opportunities, and thus to support better informed decision-making related to cell and gene-based therapies.
• To facilitate better decision-making at key points in development of new therapies and thus enable improved product development, by providing the research community and regulatory and healthcare authorities with an information source on the practical steps needed for cell and gene therapy development.
To achieve our aims, EuroGCT will adopt a highly structured system for coordinated management of information related to cell and gene therapy development and, from this, will implement an ambitious programme of online and direct stakeholder information provision and engagement. All outputs will be delivered in 7 European languages, to ensure broad accessibility, and will be rigorously evaluated against measurable objectives throughout the project duration. The proposed consortium comprises leading cell and gene therapy-related organisations and basic and clinical research labs across Europe, including new member states; together with experts in product development, ethical, legal and societal issues, and in evaluating clinical outcomes; patient representatives; and science communicators. It thus is uniquely placed to develop a world-leading cell and gene therapy information resource and to meet the challenge outlined in Topic SC1-HCO-19-2020.

Invito a presentare proposte

H2020-SC1-BHC-2018-2020

Vedi altri progetti per questo bando

Bando secondario

H2020-SC1-2020-Single-Stage-RTD

Meccanismo di finanziamento

CSA - Coordination and support action

Coordinatore

THE UNIVERSITY OF EDINBURGH
Contribution nette de l'UE
€ 1 710 483,75
Indirizzo
OLD COLLEGE, SOUTH BRIDGE
EH8 9YL Edinburgh
Regno Unito

Mostra sulla mappa

Regione
Scotland Eastern Scotland Edinburgh
Tipo di attività
Higher or Secondary Education Establishments
Collegamenti
Costo totale
€ 1 710 483,75

Partecipanti (46)